or 15 cm plates. Complete media was replaced with serum-free media containing defined nutrients only. After 5 days in culture, debris was cleared from vesicles and particles by low-speed centrifugation and filtration, and particles and vesicles were harvested using ultracentrifugation. The resulting P70 was sandwiched between a 2.5 M sucrose cushion and a 0.4-2.0 M linear sucrose gradient, and immediately centrifuged for 0-100+ hours at 100,000g. The observed separation of the major particles investigated is illustrated on the right. B. One-ml gradient fractions were assessed for weight. The gray bar signifies the typically expected fractions containing exosomes as defined by equilibrium density. A. P70 preparations were subjected to filtration through the indicated size cut-off filters prior to buoyancy gradient centrifugation, and specified proteins and miRNA species were measured by fluorescent quantitation or quantitative RT-PCR respectively. B. P70 preparations were subjected to Ribonuclease (P70+RNAseA) or mock treatment (P70), and CD81 abundance measured on gradient fractions. C. Loss of indicated miRNAs was quantified after ribonuclease treatment before (as exported) or after (purified RNA) Trizol extraction from particles. N=2. Note that miRNA in P70 remained resistant to RNAse, while added SYNTH RNA was severely degraded. Upon extraction from P70, all miRNAs were degraded by RNaseA. Therefore, all miRNAs that we tested, including nonvesicular miR-1246, are in a form that is protected from RNaseA degradation, confirming that these miRNAs, which we have identified as candidate makers of breast cancer in body fluids (30) 
